ODI Pharma AB: Publication of interim report Q3 2021/2022
ODI Pharma AB (“ODI” or the “Company”) hereby publishes its interim report for the period July 2021 – March 2022. The report is available as an attached document to this press release and on the Company’s website (www.odipharma.com). Below is a summary of the report.Third quarter (2022-01-01 – 2022-03-31) The Group's net sales amounted to SEK 71,298 (0). The Group's loss after financial items amounted to SEK -2,344,281 (-41,280). Result per share amounted to SEK -0.15 (0).* The solidity as of 2022-03-31 was 95.11 % (99.63 %).** Nine months (2021-07-01 – 2022-03-31) The